# Roles of immune cell metabolism in rheumatoid arthritis

**Authors:** Rui Xie, Zeping Chen, Shufang Deng, Xiaofeng Jiang, Yue Feng, Wei Zhao

PMC · DOI: 10.3389/fimmu.2026.1763130 · Frontiers in Immunology · 2026-02-04

## TL;DR

This paper reviews how immune cell metabolism influences rheumatoid arthritis, highlighting new insights into metabolic pathways and potential therapeutic strategies.

## Contribution

The paper provides a comprehensive review of immune cell metabolism's role in rheumatoid arthritis and emerging metabolic interventions.

## Key findings

- Aberrant glycolysis, lipid reprogramming, and amino acid catabolism drive immune cell dysfunction in RA.
- Metabolites like lactate and succinate act as immunomodulatory signals, worsening inflammation and tissue damage.
- Targeting metabolic checkpoints shows promise in restoring immune tolerance and reducing RA severity.

## Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Recent advances reveal that immune cell metabolism plays a pivotal role in shaping RA pathogenesis. Aberrant glycolysis, lipid reprogramming, and amino acid catabolism drive functional alterations in T cells, B cells, macrophages, neutrophils, and fibroblast-like synoviocytes (FLSs), promoting inflammatory cytokine production, angiogenesis, and autoantibody generation. Key metabolites—such as lactate, succinate, and glutamine—not only serve as energy substrates but also act as immunomodulatory signals via the HIF-1α, PI3K/AKT/mTOR, and NF-κB pathways, exacerbating immune dysfunction and tissue damage. The plasticity of metabolic states contributes to Treg/Th17 imbalance, proinflammatory macrophage polarization, and FLS hyperactivation. Targeting these metabolic checkpoints has shown promise in restoring immune tolerance and alleviating disease severity. This review summarizes the complex interplay between immune cell metabolism and RA pathophysiology, highlights mechanistic insights into immunometabolic reprogramming, and discusses emerging metabolic interventions that may complement conventional RA therapies.

## Linked entities

- **Proteins:** HIF1A (hypoxia inducible factor 1 subunit alpha), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), MTOR (mechanistic target of rapamycin kinase), NFKB1 (nuclear factor kappa B subunit 1)
- **Chemicals:** lactate (PubChem CID 61503), succinate (PubChem CID 160419), glutamine (PubChem CID 738)
- **Diseases:** rheumatoid arthritis (MONDO:0008383)

## Full-text entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, HKDC1 (hexokinase domain containing 1) [NCBI Gene 80201] {aka RP92}, PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) [NCBI Gene 5209] {aka IPFK2, PFK2, iPFK-2}, MIR22 (microRNA 22) [NCBI Gene 407004] {aka MIRN22, hsa-mir-22, miR-22}, ANGPTL4 (angiopoietin like 4) [NCBI Gene 51129] {aka ARP4, FIAF, HARP, HFARP, NL2, PGAR}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Mir155 (microRNA 155) [NCBI Gene 387173] {aka Mirn155, mir-155, mmu-mir-155}, PFKM (phosphofructokinase, muscle) [NCBI Gene 5213] {aka ATP-PFK, GSD7, PFK-1, PFK-A, PFK1, PFKA}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}
- **Diseases:** hyperplasia (MESH:D006965), immune dysregulation (OMIM:614878), joint destruction (MESH:D008105), chronic (MESH:D002908), tissue injury (MESH:D017695), heart disease (MESH:D006331), immune dysfunction (MESH:D007154), synovitis (MESH:D013585), rheumatic diseases (MESH:D012216), macrophage injury (MESH:D055501), bone (MESH:D001847), bone erosion (MESH:D014077), joint damage (MESH:D007592), RA (MESH:D001172), arthritis (MESH:D001168), joint deformities (MESH:D016916), B cell deficiency (MESH:D015448), arthritic (MESH:D015535), cartilage (MESH:D002357), hypoxia (MESH:D000860), autoimmune (MESH:D001327), hypoxic (MESH:D002534), Rheumatoid (MESH:D011695), functional disability (MESH:D003291), ischemic (MESH:D002545), articular damage (MESH:D012213), CIA (MESH:D001169), complications (MESH:D008107), Inflammatory (MESH:D007249)
- **Chemicals:** Berberine (MESH:D001599), ROS (MESH:D017382), Glucose (MESH:D005947), citrate (MESH:D019343), Glutamine (MESH:D005973), ATP (MESH:D000255), naringenin (MESH:C005273), LPS (MESH:D008070), Lipid (MESH:D008055), NADPH (MESH:D009249), Amino acid (MESH:D000596), Fatty acid (MESH:D005227), FAO (-), alkaloid (MESH:D000470), SIN (MESH:C009271), hyaluronic acid (MESH:D006820), cholesterol (MESH:D002784), apigenin (MESH:D047310), paeoniflorin (MESH:C015423), Lactate (MESH:D019344), TCA (MESH:D014233), Pentose phosphate (MESH:D010428), fructose-2,6-bisphosphate (MESH:C027652), itaconate (MESH:C005229), succinate (MESH:D019802), oxygen (MESH:D010100)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** DBA/1 — Mus musculus (Mouse), Finite cell line (CVCL_6496), fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913156/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12913156/full.md

## References

135 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913156/full.md

---
Source: https://tomesphere.com/paper/PMC12913156